Lees Pharmaceutical Holdings Limited - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2014', provides an overview of the Lee's Pharmaceutical Holdings Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lee's Pharmaceutical Holdings Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lee's Pharmaceutical Holdings Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lee's Pharmaceutical Holdings Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lee's Pharmaceutical Holdings Limited's pipeline products

Reasons to buy

- Evaluate Lee's Pharmaceutical Holdings Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lee's Pharmaceutical Holdings Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lee's Pharmaceutical Holdings Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lee's Pharmaceutical Holdings Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lee's Pharmaceutical Holdings Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lee's Pharmaceutical Holdings Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Lee's Pharmaceutical Holdings Limited Snapshot 6
Lee's Pharmaceutical Holdings Limited Overview 6
Key Information 6
Key Facts 6
Lee's Pharmaceutical Holdings Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Lee's Pharmaceutical Holdings Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Lee's Pharmaceutical Holdings Limited - Pipeline Products Glance 14
Lee's Pharmaceutical Holdings Limited - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Lee's Pharmaceutical Holdings Limited - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Lee's Pharmaceutical Holdings Limited - Early Stage Pipeline Products 18
IND/CTA Filed Products/Combination Treatment Modalities 18
Preclinical Products/Combination Treatment Modalities 19
Lee's Pharmaceutical Holdings Limited - Drug Profiles 20
procarbazine hydrochloride 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
trazodone hydrochloride 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
prulifloxacin 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
gimatecan 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
istaroxime 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RGN-259 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
rostafuroxin 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ZK-001 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ZK-010 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ZK-011 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ZK-012 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ZK-014 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ZK-016 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ZK-013 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ZK-003 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ZK-002 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ZK-004 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ZK-009 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ZK-015 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Lee's Pharmaceutical Holdings Limited - Pipeline Analysis 45
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Target 45
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration 47
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Molecule Type 48
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Mechanism of Action 49
Lee's Pharmaceutical Holdings Limited - Recent Pipeline Updates 51
Lee's Pharmaceutical Holdings Limited - Dormant Projects 56
Lee's Pharmaceutical Holdings Limited - Discontinued Pipeline Products 58
Discontinued Pipeline Product Profiles 58
gimatecan 58
Lee's Pharmaceutical Holdings Limited - Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Lee's Pharmaceutical Holdings Limited, Key Information 6
Lee's Pharmaceutical Holdings Limited, Key Facts 6
Lee's Pharmaceutical Holdings Limited - Pipeline by Indication, 2014 9
Lee's Pharmaceutical Holdings Limited - Pipeline by Stage of Development, 2014 10
Lee's Pharmaceutical Holdings Limited - Monotherapy Products in Pipeline, 2014 11
Lee's Pharmaceutical Holdings Limited - Partnered Products in Pipeline, 2014 12
Lee's Pharmaceutical Holdings Limited - Partnered Products/ Combination Treatment Modalities, 2014 13
Lee's Pharmaceutical Holdings Limited - Pre-Registration, 2014 14
Lee's Pharmaceutical Holdings Limited - Phase III, 2014 15
Lee's Pharmaceutical Holdings Limited - Phase II, 2014 16
Lee's Pharmaceutical Holdings Limited - Phase I, 2014 17
Lee's Pharmaceutical Holdings Limited - IND/CTA Filed, 2014 18
Lee's Pharmaceutical Holdings Limited - Preclinical, 2014 19
Lee's Pharmaceutical Holdings Limited - Pipeline by Target, 2014 46
Lee's Pharmaceutical Holdings Limited - Pipeline by Route of Administration, 2014 47
Lee's Pharmaceutical Holdings Limited - Pipeline by Molecule Type, 2014 48
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Mechanism of Action, 2014 50
Lee's Pharmaceutical Holdings Limited - Recent Pipeline Updates, 2014 51
Lee's Pharmaceutical Holdings Limited - Dormant Developmental Projects,2014 56
Lee's Pharmaceutical Holdings Limited - Discontinued Pipeline Products, 2014 58
Lee's Pharmaceutical Holdings Limited, Subsidiaries 59